ASH Clinical News Hematology Pipeline Update: Drug Updates from the | Page 13
EMPLICITI + Rd: Progression-Free Survival (Minimum follow-up of 24 months)1
Probability Progression-Free (%)
100
30% RELATIVE RISK REDUCTION
%
68
1-YEAR
90
HR 0.70; 95% CI (0.57, 0.85)
P=0.0004* (Co-primary endpoint)
PFS RATE
80
41%
70
60
2-YEAR
PFS RATE
57%
50
40
30
27%
20
10
EMPLICITI + Rd (n=321)
Rd (n=325)
0
0
4
8
12
16
20
24
Progression-Free Survival (Months)
ERd
321
279
232
195
157
128
Rd
325
249
192
158
123
89
28
32
36
85
42
12
1
48
21
7
40
Subjects at risk
Significantly more patients responded to therapy with EMPLICITI in combination with Rd vs Rd alone1
At the time of this PFS analysis, there were fewer deaths in the ERd arm vs the Rd arm
(94 [29%] vs 116 [36%])1
A Phase 3, randomized, open-label study conducted to evaluate the efficacy and safety of EMPLICITI in combination with
Rd in 646 patients (EMPLICITI + Rd, n=321; Rd, n=325) with multiple myeloma who had received 1 to 3 prior therapies.1
*p-value based on the log-rank test stratified by ß2 microglobulins (<3.5 mg/L vs ≥3.5 mg/L), number of prior lines of therapy (1 vs 2 or 3), and prior
immunomodulatory therapy (no vs prior thalidomide only vs other).1
†
Assessed by blinded Independent Review Committee per European Group for Blood and Marrow Transplantation (EBMT) criteria.1
‡
p-value based on the Cochran-Mantel-Haenszel chi-square test stratified by ß2 microglobulins (<3.5 mg/L vs ≥3.5mg/L), number of prior lines of
therapy (1 vs 2 or 3), and prior immunomodulatory therapy (no vs prior thalidomide only vs other).1
CI=confidence interval; HR=hazard ratio; ORR=overall response rate; PFS=progression-free survival; Rd=lenalidomide + dexamethasone.
References: 1. EMPLICITI [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2. Lonial S, Dimopoulos M, Palumbo A, et al; for the
ELOQUENT-2 Investigators. N Engl J Med. Elotuzumab therapy for relapsed or refractory multiple myeloma. 2015;373(7):621–631.
Call
1-844-EMPLICITI
(1-844-367-5424)
NEW
Visit
EmplicitiRx.com
EMPLICITI and the related logo are trademarks of Bristol-Myers Squibb Company.
© 2015 Bristol-Myers Squibb Company. All rights reserved. 689US1500492-07-01 12/15